Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
Epsilogen has raised €37M across 1 funding round from 5 investors, most recently a Series B round in Mar 2022. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-03-02 | Series B | €37M |
| 3B Future Health Fund,British Patient Capital,Caribou Property,Novartis Venture Fund,Schroders Capital |
| View deal → |
